OncLive TV

Alison R. Sehgal, MD, discusses key targetable alterations in acute myeloid leukemia.

Emily C. Ayers, MD, hematologist​/oncologist​, assistant professor, University of Virginia Health, discusses the evolving treatment landscape in chronic lymphocytic leukemia.

Brian T. Hill, MD, PhD, discusses the utility of BTK inhibitors in relapsed/refractory mantle cell lymphoma.

John O. Mascarenhas, MD, discusses the role of genetic testing in myeloproliferative neoplasms.

Caitlin Costello, MD, discusses considerations for induction therapy selection in multiple myeloma.

Ruben A. Mesa, MD, discusses the potential role of momelotinib in alleviating myelofibrosis-associated anemia.

Joseph Kim, MD, discusses the evolution of therapy in metastatic hepatocellular carcinoma.

Nilanjan Ghosh, MD, PhD, director of the Lymphoma Program and a physician with Levine Cancer Institute, discusses unmet needs with CAR T-cell therapy in diffuse large B-cell lymphoma.

Neeraj Agarwal, MD, discusses unmet needs in metastatic hormone-sensitive prostate cancer.

Jeffrey S. Weber, MD, PhD, ​deputy director and co-director of the melanoma program, Laura and Isaac Perlmutter Professor of Oncology, Department of Medicine, NYU Langone Health’s Perlmutter Cancer Center, 2016 Giant of Cancer Care® in Melanoma, discusses the treatment of lactate dehydrogenase (LDH)​–high melanoma.

Allison Winter, MD, hematologist/medical oncologist, Cleveland Clinic, discusses the role of frontline targeted therapies in chronic lymphocytic leukemia.

Sarah Nagle, MD, assistant professor of medicine, School of Medicine, Oregon Health & Science University, discusses investigational cellular therapies in multiple myeloma.

Jia Ruan, MD, PhD, associate professor of clinical medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses treatment considerations for patients with relapsed/refractory mantle cell lymphoma.

Firas El Chaer, MD, discusses the potential utility of combination strategies with ruxolitinib in patients with myeloproliferative neoplasms.

Joseph Kim, MD, discusses curative therapeutic options in hepatocellular carcinoma.

Joshua Brody, MD, discusses management strategies for the toxicities associated with CAR T-cell therapy in mantle cell lymphoma.

Paul C. Boutros, PhD, MBA, discusses the utility of genetic testing in prostate cancer.

Mateusz Opyrchal, MD, PhD, discusses the current state of biomarkers in triple-negative breast cancer.

Joseph Mikhael, MD, discusses remaining challenges in high-risk multiple myeloma.

Jason J. Luke, MD, FACP, discusses the role of molecular testing in melanoma.

Yelena Y. Janjigian, MD, discusses the importance of selecting ​an optimal first-line therap​y in gastric cancer.

Kathleen ​A. Dorritie, MD, discusses transplant eligibility in multiple myeloma.

Daniel W. Lin, MD, discusses the limitations of currently available biomarkers in prostate cancer.

Timothy Price, MBBS, DHthSc, FRACP, discusses challenges faced during the CodeBreaK 100 trial in gastrointestinal cancers.

Jamie E. Chaft, MD, discusses the rationale behind the ​OPAL trial in EGFR-mutant non–small cell lung cancer.

Jia Ruan, MD, PhD, discusses treatment considerations in mantle cell lymphoma.

Cathy Eng, MD, FACP, FASCO, discusses the features of high-risk colorectal cancer.

John O. Mascarenhas, MD, discusses emerging agents in myelofibrosis.

Jamie E. Chaft, MD, a thoracic medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the next steps of osimertinib research in EGFR-mutant non–small cell lung cancer.

Masahiro Tsuboi, MD, a surgeon at the National Cancer Center Hospital East in Japan, discusses findings from the phase 3 ADAURA trial in EGFR-mutant non–small cell lung cancer.